Logo

ActivX and Kyorin to Study Metabolic Disorders

Jan 08, 2004

NEW YORK, Jan.8 (GenomeWeb News) - ActivX Biosciences and Kyorin Pharmaceutical have signed a research agreement to study compounds for metabolic disorders, Kyorin said Tuesday.

 

ActivX, based in La Jolla, Calif., will use its proteomics technology to analyze the activity and toxicity mechanisms of compounds developed by Kyorin of Tokyo to treat metabolic disorders.

 

The two companies have already been collaborating since 2002  to study new drugs for type II diabetes.

 

Breaking News
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.